Core Viewpoint - FTSE Russell announced quarterly review changes for multiple indices, effective after the close on September 19, 2025, with significant implications for the FTSE China A50 Index [2][5]. Group 1: Index Changes - The FTSE China A50 Index will include stocks such as BeiGene-U, NewEase, WuXi AppTec, and Zhongji Xuchuang, which are primarily from the pharmaceutical and AI computing sectors [3][6]. - Stocks removed from the FTSE China A50 Index include China Nuclear Power, China Unicom, Guodian Nari, and Wanhua Chemical [6][7]. - The FTSE China A50 Index consists of the 50 largest stocks listed on the Shanghai and Shenzhen exchanges, reviewed quarterly [7]. Group 2: Stock Performance - BeiGene-U has doubled in value this year, with a growth rate of 102.51%, and a market capitalization of approximately 466.4 billion [7]. - WuXi AppTec also experienced a doubling in its stock price, while NewEase surged over three times, and Zhongji Xuchuang increased by over 240%, with a market cap exceeding 470 billion [7]. Group 3: Market Trends - The inclusion of stocks in the FTSE Russell indices often leads to significant buying pressure from index-tracking funds, particularly around the effective date of the changes [8]. - The AI computing sector is expected to see explosive growth in demand as it plays a crucial role in the AI industry, impacting various segments of the supply chain [11]. - The pharmaceutical sector is experiencing a shift towards innovation-driven growth, with a focus on value creation through new drug models, which is anticipated to result in greater market capitalization increases compared to previous cycles [11].

创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），指数涨跌幅为20%，该指数从创业板 市场中选取涉及生物制药、医疗器械、医疗服务等领域的上市公司证券作为指数样本，以反映创业板医 药行业相关上市公司证券的整体表现。创医药指数聚焦于高研发投入、技术领先的医药企业，充分体现 了医药行业在创业板的创新及成长特性。 东海证券指出，近期医药生物板块表现良好，医疗服务、医疗器械子板块涨幅居前。国家医保局连续召 开两场医保支持创新药械座谈会，明确通过统一新设医疗服务价格项目、研究实行新上市药品首发价格 机制等举措，推动高水平科技创新成果加快进入临床应用，支持中国药械高质量发展。自2025年6月药 监局审议通过《关于优化全生命周期监管支持高端医疗器械创新发展的举措》以来，顶层设计对创新医 疗器械的支持态度日渐明确，意在将有限的医保资源"真支持创新、支持真创新、支持差异化创新"。随 着政策引导下的有序竞争、良性竞争逐渐占据主导地位，医疗器械板块的盈利和估值水平有望迎来整体 提升。 每日经济新闻 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市 ...